Evidence map›Paper›PMID 40509344›Full record

ArticleMolecules (Basel, Switzerland)2025

Anticancer Effects of Withanolides: In Silico Prediction of Pharmacological Properties.

Gustavo Werneck de Souza E Silva, André Mesquita Marques, André Luiz Franco Sampaio

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gustavo Werneck de Souza E SilvaLaboratório de Farmacologia Molecular, Farmanguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil.ORCID 0000-0002-1936-3560
André Mesquita MarquesLaboratório de Tecnologia Para Biodiversidade em Saúde/TecBio, Farmanguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil.ORCID 0000-0001-5444-5724
André Luiz Franco SampaioLaboratório de Farmacologia Molecular, Farmanguinhos, Fundação Oswaldo Cruz (FIOCRUZ), Rua Sizenando Nabuco 100, Manguinhos, Rio de Janeiro 21041-250, Brazil.ORCID 0000-0002-5596-6174

Funding

National Council for Scientific and Technological Development 440018/2022-6National Council for Scientific and Technological Development 447630/2024-5
6 · The paper itself

Abstract

Withanolides are a class of naturally occurring C-28 ergostane steroidal lactones with an abundance of biological activities, and their members are promising candidates for antineoplastic drug development. The ADMET properties of withanolides are still largely unknown, and in silico predictions can play a crucial role highlighting these characteristics for drug development, shortening time and resources spent on the development of a drug lead. In this work, ADMET properties of promising antitumoral withanolides were assessed. Each chemical structure was submitted to the prediction tools: SwissADME, pkCSM-pharmacokinetics, admetSAR v2.0, and Molinspiration Cheminformatics. The results indicate a good gastrointestinal absorption rate, inability to cross the blood-brain barrier, CYP3A4 metabolization, without inhibition of other P450 cytochromes, high interaction with nuclear receptors, and a low toxicity. It was also predicted for the inhibition of pharmacokinetics transporters and some ecotoxicity. This demonstrates a viability for oral drug development, with low probabilities of side effects.

Indexed as

Antineoplastic AgentsWithanolidesBlood-Brain BarrierComputer SimulationHumansMolecular StructureAntineoplastic AgentsWithanolidesADMETcancerdrug developmentnatural productswithaferinwithanolides

Identifiers

PMID40509344
PMCPMC12156425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.